Racura Oncology (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Racura Oncology Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Racura Oncology (ASX: RAC)
Latest News
Healthcare Shares
Why the Race Oncology (ASX:RAC) share price surged 7% today
Share Gainers
Why is the Race Oncology (ASX:RAC) share price up 18% in a month?
Healthcare Shares
What's going on with the Race Oncology (ASX:RAC) share price today?
Share Market News
Race Oncology (ASX:RAC) share price slumps on quarterly update
Healthcare Shares
The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
Healthcare Shares
The Race Oncology (ASX:RAC) share price is stumbling today
Share Gainers
Why the Race Oncology (ASX:RAC) share price is charging higher today
Share Gainers
Why Ecofibre, MoneyMe, Nearmap, & Race Oncology shares are storming higher
Healthcare Shares
Here's why the Race Oncology (ASX:RAC) share price is leaping higher
Healthcare Shares
Why the Race Oncology (ASX:RAC) share price is frozen
Share Gainers
Why the Race Oncology (ASX:RAC) share price is racing higher
Share Gainers
Why Ampol, Netwealth, Orocobre, & Race Oncology shares are storming higher
Frequently Asked Questions
-
No, Racura Oncology does not pay dividends at this time.
-
Sydney-headquartered Racura Oncology listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.
Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.
